Leo Pharma brings in old friends and new blood for eczema treatment launch
While Leo Pharma waits for a response to its approval application for eczema treatment Adtralza in the US, it is launching the treatment in the EU, where Head of Europe Monica Shaw can put the experience from launching psoriaris treatment Kyntheum to good use.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Leo Pharma is making the most of its EU approval for eczema treatment Adtralza (tralokinumab) coming in two weeks earlier than expected.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis moves forward with phase III drug
For subscribers
